Rapidly autopsied postmortem human brain and blood specimens from sporadic Alzheimer’s disease (AD), Autosomal Dominant AD, and Controls

The National Institutes of Health (NIH) intends to negotiate and award a contract without providing for full and open competition to Banner Health for the provision of rapidly autopsied postmortem human brain and blood specimens from sporadic Alzheimer’s disease (AD), Autosomal Dominant AD, and Controls. The contract will require Banner Health to provide specimens that meet specific criteria, including a postmortem interval of less than or equal to 3 hours, minimal and uniform fixation, and the ability to withstand harsh staining and stripping procedures. • The contract will be awarded under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures. • The contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 2005-99-1, July 16, 2018. • The contract is expected to be awarded without full and open competition due to the unique requirements of the project. • Interested parties may submit a capability statement, proposal, or quotation, which will be considered by the agency.